ClinicalTrials.gg
Not yet recruitingNCT07944781PACT-MDMAUpdated Nov 18, 2026

MDMA-Assisted Couple Psychotherapy for PTSD in First Responders: A Phase I Feasibility Study (PACT-MDMA)

A Phase 1 interventional study of MDMA hydrochloride, non-racemic 75:25 R(-)/S(+) (Laneo 2.0) and Process-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA) in Post-Traumatic Stress Disorder, sponsored by Jeremie Richard. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Jeremie Richard · Phase 1, Interventional, and Treatment

How we know

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada — 34 open to participants now, 42 under way, 2 of them phase 3. Stress Disorders, Post-Traumatic · Canada.

Planned enrollment
86th of 113
20 · median 54
Started
2027
with 1 other
Phase 1
3 of 127
3 open now
Primary completion
2028-10
later than 37 of 41 live
Registered
126th of 127
by date

Among the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, this one is the 86th largest by planned enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2027, is one of 3 in phase 1, reaches primary completion later than 37 of the 41 other live ones, and was the 126th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

34 of the 127 studies in Stress Disorders, Post-Traumatic with a site in Canada are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 203 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Stress Disorders, Post-Traumatic with a site in Canada, or all of them as a file.
02

Study summary

This study is the first step of a research programme on a new treatment for first responders with post-traumatic stress disorder (PTSD): couple therapy in which both partners take MDMA, under medical supervision, in three of fourteen sessions. The treatment is called Process-Centred MDMA-Assisted Couple Psychotherapy, or PACT-MDMA.

Current treatments help many people with PTSD, but many drop out or improve only in part, and few treatments work directly on the relationship, which PTSD strains and which can help recovery. MDMA-assisted therapy has been tested in large trials in the United States, but these studies' designs have been criticised, and the therapy component of the treatment has rarely been specified or measured. No Canadian study has tested MDMA-assisted therapy in first responders, and none has tested it with couples.

This feasibility study at the University of Ottawa will enrol six to ten couples in which one partner is a current or former first responder with PTSD. It asks whether the treatment can be delivered safely, whether couples can be recruited and kept in the study, and whether the sessions and measures work as planned. It does not aim to prove that the treatment works. Two exploratory hypotheses will be examined: that the partner with PTSD will show a reduction in clinician-rated PTSD severity from baseline to the end of treatment that is maintained six months later, and that the other partner will accommodate PTSD symptoms less while both partners report a better relationship over the same period.

A nurse is present and a physician on call during every MDMA session; all sessions are recorded so that the therapy can be checked for fidelity to its written principles; and the research, therapy and medical roles are kept separate. If this phase succeeds, a second phase would compare PACT-MDMA with standard PTSD therapy in about 24 couples in Ottawa and Montreal, and a third would extend the study to several Canadian sites.

Read the detailed description

Design. Single-site, single-arm, open-label, mixed-methods Phase I feasibility study with repeated measures at baseline (T0), after each of three treatment cycles (T1 to T3) and at 1, 3 and 6 months after the closing session (T4 to T6). Six to ten couples (12 to 20 participants) will be enrolled. The couple is the unit of treatment; both partners receive the full intervention, including MDMA.

Rationale for the design. Randomisation, placebo and blinding are not used: blinding is not practically possible, since therapists and participants recognise the subjective effects of MDMA, and a placebo or sham-therapy control was judged neither practical nor ethically appropriate for an intensive relational and pharmacological intervention at the feasibility stage. Outcomes are read against published results of cognitive-behavioural conjoint therapy, individual trauma-focused therapies and MDMA-assisted therapy trials. The design responds to the concerns raised in the U.S. FDA review of MDMA-assisted therapy (2024): functional unblinding and expectancy are assumed present and measured (treatment credibility and expectancy at baseline, acute subjective drug effects at each MDMA session); research, therapy and medical functions are assigned to three teams with no overlap in personnel; prior MDMA or psychedelic use is an exclusion criterion; therapists deliver a common protocol under supervision and fidelity is rated from recordings; outcomes are assessed by independent assessors; a 6-month follow-up assesses medium-term durability.

Screening and enrolment. Recruitment is through online advertising, professional networks and printed material in clinics specialising in PTSD near the site. Screening has three stages: a coordinator call (study overview, preliminary eligibility); medical screening by the study physician or delegate (medical and psychiatric history, cardiovascular risk, medications and substances); and a psychotherapeutic intake assessment of both partners (individual stability, relational safety, motivation, capacity for conjoint participation). Participants taking contraindicated medications complete a supervised taper under their own physician before eligibility is confirmed. Final medical eligibility rests with the Medical Director. Each couple receives a CAD 50 gift card on completing the post-treatment questionnaires and CAD 100 on completing the 6-month follow-up.

Intervention. PACT-MDMA is a continuous course of conjoint psychotherapy in which three MDMA-assisted cycles are embedded. Both partners attend all 14 sessions: an introductory session; three cycles each comprising a preparatory session, a full-day MDMA session (6 to 8 hours) and two integration sessions; and a closing session. MDMA sessions are about four weeks apart. Each couple is treated by the same two co-therapists throughout. Sessions are in person, except the introductory and closing sessions, which may be held by telehealth. The psychotherapy is trauma-focused, conjoint and process-centred: participant-led, with safety taking precedence over outcome, consent ongoing and revocable, and preparation and integration treated as essential components rather than adjuncts to dosing. All sessions, including MDMA sessions, are audio- and video-recorded as a condition of participation, for supervision, fidelity rating and safety review.

Investigational product and medical oversight. Laneo™ 2.0 MDMA (MDMA hydrochloride, 50 mg oral capsules; PharmAla Biotech) as a dose of 150 mg, three 50 mg capsules, the same for all participants, with one optional supplemental dose of 50 mg (one capsule) 90 minutes after the initial dose, conditional on medical clearance, the Therapy Team's agreement and the agreement of both partners, given to both partners or to neither (maximum 200 mg per session) ; three dosing sessions per participant (maximum cumulative dose 600 mg MDMA HCl). On each MDMA day a Medical Team member conducts a same-day assessment of each partner and the Medical Director authorises dosing. Vital signs are taken before dosing and before discharge; the co-therapy team observes continuously; on-site nursing staff and an on-call study physician are immediately available; an emergency kit is on site. Predefined stopping rules operate at session, participant and study level, including suspension of enrolment and dosing pending review and notification of the REB and Health Canada. Adverse events are classified by the Medical Team for severity, seriousness, expectedness and relatedness and reported to the REB and Health Canada within the Division 5 timelines.

Analysis. Feasibility is summarised as the numbers screened, eligible, enrolled and retained at each assessment point, with reasons for exclusion and withdrawal; protocol adherence as the proportion of scheduled sessions completed and the frequency and nature of protocol variations, deviations and stopping-rule events; safety as the frequency, severity, seriousness and relatedness of adverse events, reported separately for index participants and partners. Quantitative outcome data are analysed with descriptive statistics and within-subject pre-post comparisons; analyses are exploratory and hypothesis-generating. Qualitative interview data are analysed thematically. The study is not powered to detect statistically significant effects and no formal power calculation applies.

Data management. Data are collected in REDCap and held in encrypted, access-controlled University of Ottawa storage. Participants are identified by a couple code and partner suffix; a single cross-reference file linking identities to codes is held by the project coordinator, separately from research data. Research, medical, therapy, drug-accountability and recording records are held in separate stores with role-based access. Essential records are retained for 15 years as required for Division 5 clinical trials. Results are reported in aggregate with small-sample disclosure safeguards.

Governance and regulation. The sponsor is Dr Jeremie Richard, sponsor-investigator, of the School of Psychology, University of Ottawa; the study is conducted at the School of Psychology's Laboratory for Psychedelic Clinical Research. It requires a Clinical Trial Application and No Objection Letter from Health Canada (Food and Drug Regulations, Division 5), an exemption under section 56(1) of the Controlled Drugs and Substances Act, research ethics board approval and institutional sign-off before enrolment. This feasibility study is the first phase of a planned three-phase programme (feasibility, pilot randomised trial, multi-site trial).

03

Conditions studied

  • Post-Traumatic Stress Disorder

Keywords

  • MDMA
  • 3,4-methylenedioxymethamphetamine
  • psychedelic-assisted psychotherapy
  • couples therapy
  • conjoint therapy
  • first responders
  • emergency responders
  • post-traumatic stress disorder
  • feasibility study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (both partners unless stated):

  • Aged 18 years or older
  • One partner (the index participant) is a current or former first responder with a diagnosis of post-traumatic stress disorder or complex post-traumatic stress disorder
  • In a relationship of at least 12 months and currently cohabiting
  • Fluent in French or English (reading, writing and speaking)
  • Willing to attend the therapy in person at the study site and to have all sessions audio- and video-recorded
  • Able to name a supportive person not participating in the study as emergency contact
  • Willing and able to provide and to take part in all study procedures
  • The study is inclusive of all gender identities, sexual orientations, cultural backgrounds and religious affiliations

Exclusion Criteria (both partners, since both receive MDMA):

  • Current diagnosis of a substance use disorder (moderate to severe)
  • Current use of psychoactive medications (e.g., SSRIs, MAOIs), herbal supplements, or prescription or non-prescription medications that cannot be safely tapered before the study
  • Current or previous use of MDMA or other psychedelics
  • Uncontrolled hypertension, significant cardiovascular disease, or another medical condition contraindicating MDMA
  • Pregnancy or breastfeeding
  • Current participation in another clinical trial
  • History of psychotic disorder or of a disorder with psychotic features, bipolar I disorder, or borderline personality disorder
  • Active suicidal ideation, recent suicide attempt, or danger to others
  • Cognitive impairment that limits the ability to provide informed consent or to take part in therapy
  • Current conventional or PTSD-focused psychotherapy, or another procedure likely to affect study outcomes (e.g., other psychedelic-assisted therapy, electroconvulsive therapy, transcranial magnetic stimulation)
  • Relational ambivalence, including current plans to separate or divorce
  • High-conflict relationship including physical violence

Final medical eligibility rests with the Medical Director, who may exclude on clinical judgement even where formal criteria are met.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    PACT-MDMA

    Couples in which one partner is a current or former first responder with PTSD. Both partners receive Process-Centred MDMA-Assisted Couple Psychotherapy: 14 conjoint sessions delivered by the same two co-therapists, comprising an introductory session, three treatment cycles (preparatory session, full-day MDMA session, two integration sessions) about four weeks apart, and a closing session. In each MDMA session both partners receive an oral dose of 150 mg MDMA hydrochloride, with one optional 50 mg supplemental dose 90 minutes later, given to both partners or to neither.

    Drug: MDMA hydrochloride, non-racemic 75:25 R(-)/S(+) (Laneo 2.0) · Behavioral: Process-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA)

Interventions

  • DrugMDMA hydrochloride, non-racemic 75:25 R(-)/S(+) (Laneo 2.0)

    Laneo 2.0 MDMA (75% R(-)-MDMA / 25% S(+)-MDMA hydrochloride; PharmAla Biotech Inc.), 50 mg hard oral capsules; a non-racemic composition used clinically in Australia. Oral dose of 150 mg MDMA HCl (three 50 mg capsules) per MDMA session, the same for all participants regardless of body weight or sex, with one optional 50 mg supplemental (booster) dose (one capsule) 90 minutes after the initial dose, conditional on same-day medical clearance, the Therapy Team's agreement and both partners' agreement, and given to both partners or to neither (maximum 200 mg per session). Capsules are ingested intact under the direction and supervision of an authorised Medical Team member. Three MDMA sessions per participant, about four weeks apart (maximum cumulative dose 600 mg MDMA HCl). Both partners of each couple are dosed concurrently.

    Also known as: LaNeo MDMA

  • BehavioralProcess-Centred MDMA-Assisted Couple Psychotherapy (PACT-MDMA)

    Conjoint, trauma-focused, process-centred psychotherapy delivered to both partners by a co-therapy team of two therapists who remain constant across all sessions. Fourteen sessions: an introductory session (60 min); three cycles, each with a preparatory session (90 min), an MDMA session (6 to 8 h) and two integration sessions (90 min each, the first within 24 to 48 h of dosing, the second within two weeks); and a closing session (60 min). Introductory and closing sessions may be held by telehealth; all other sessions are in person. Sessions are not organised around a fixed sequence of exercises; content follows what emerges, under written principles rated for fidelity from session recordings.

06

What researchers measure

Primary outcomes

  1. Recruitment: number of couples screened, eligible and enrolled, and enrolment rate

    Numbers of couples screened, found eligible and enrolled, with reasons for exclusion; couples enrolled per month of open recruitment.

    Time frame: From the opening of recruitment through the end of enrolment (approximately 183 days after recruitment opens)

  2. Retention: proportion of enrolled couples completing the three treatment cycles and each assessment point

    Proportion of enrolled couples who complete all three treatment cycles (closing session, T3) and who complete the assessments at T1 to T6, with reasons for withdrawal.

    Time frame: From enrolment to the 6-month follow-up (T6 = day 304), with completion assessed on days 42, 70, 122, 152, 213 and 304

  3. Protocol adherence: proportion of scheduled sessions completed per protocol, and protocol variations, deviations and stopping-rule events

    Proportion of the 14 scheduled sessions completed per protocol for each couple; frequency and nature of protocol variations, deviations and applications of the session-, participant- and study-level stopping rules.

    Time frame: From the introductory session (day 14) to the closing session (T3 = day 122)

  4. Therapist fidelity to the PACT-MDMA model (PACT-MDMA Fidelity Rating Scale, PACT-FRS)

    Adherence, competence and differentiation ratings by independent raters from recordings of all MDMA sessions and a stratified sample of other sessions; therapist self-ratings; inter-rater reliability; drift events across a therapist's consecutive ratings.

    Time frame: From the introductory session (day 14) to the closing session (T3 = day 122)

  5. Safety: frequency, severity, seriousness and relatedness of adverse events

    Adverse events, serious adverse events, serious adverse reactions and suspected unexpected serious adverse reactions, classified by the Medical Team by severity, seriousness, expectedness and relatedness and including psychological and relational events, reported separately for index participants and partners.

    Time frame: From enrolment (T0 = day 0) to the 6-month follow-up (T6 = day 304)

Secondary outcomes

  1. Change in clinician-rated PTSD symptom severity (CAPS-5), index participant

    Clinician-Administered PTSD Scale for DSM-5, structured interview assessing DSM-5 PTSD diagnosis and symptom severity across the 20 DSM-5 symptoms, administered by an independent assessor to the partner with PTSD.

    Time frame: Baseline (T0 = day 0), post-treatment (T3 = day 122), and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  2. Change in self-reported PTSD symptom severity (PCL-5), both partners

    PTSD Checklist for DSM-5, 20-item self-report mapping onto the DSM-5 PTSD symptoms. Completed separately by each partner.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  3. Change in partner accommodation of PTSD symptoms (SORTS), support partner

    Significant Others' Responses to Trauma Scale, assessing partner responses and accommodation of PTSD symptoms; completed by the partner without PTSD.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  4. Change in relationship satisfaction (Couple Satisfaction Index, CSI), both partners

    Couple Satisfaction Index, self-report measure of relationship satisfaction.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  5. Change in relationship quality (Quality of Relationships Inventory, QRI), both partners

    Quality of Relationships Inventory: Support, Depth and Conflict subscales.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  6. Change in attachment anxiety and avoidance (ECR-M16), both partners

    Modified Experiences in Close Relationships scale, 16 items.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  7. Change in depressive symptoms (PHQ-9), both partners

    Patient Health Questionnaire-9, 9-item measure of depressive symptom severity.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  8. Change in anxiety symptoms (GAD-7), both partners

    Generalized Anxiety Disorder-7, 7-item measure of generalised anxiety symptom severity.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  9. Suicidal ideation and behaviour (C-SSRS), both partners

    Columbia-Suicide Severity Rating Scale; presence and severity of suicidal ideation and behaviour.

    Time frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  10. Change in experiential avoidance (BEAQ), both partners

    Brief Experiential Avoidance Questionnaire, 15-item self-report measure of experiential avoidance.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  11. Change in psychological flexibility (MPFI-24), both partners

    Multidimensional Psychological Flexibility Inventory, 24-item short form covering the six flexibility and six inflexibility processes of the Hexaflex model; higher-order flexibility and inflexibility scales.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  12. Change in posttraumatic growth (PTGI), both partners

    Posttraumatic Growth Inventory, 21 items, five domains of perceived positive change after trauma.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  13. Change in perceived social support (MOS-SSS), both partners

    Medical Outcomes Study Social Support Survey, 19-item measure of perceived functional social support.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  14. Cross-cutting psychiatric symptoms (DSM-5-TR Level 1 Cross-Cutting Symptom Measure, Adult), both partners

    23-item self-report screen of transdiagnostic symptom domains.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

  15. Alcohol, cannabis and drug use (AUDIT, CUDIT-R, DUDIT), both partners

    Brief self-report screens for hazardous alcohol, cannabis and drug use.

    Time frame: Screening (approximately 7 days before baseline), baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

Other outcomes

  1. Working alliance (WAI-SR), both partners

    Working Alliance Inventory, Short Revised, client-rated Bond, Tasks and Goals.

    Time frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122)

  2. Treatment credibility and expectancy (CEQ), both partners

    Credibility/Expectancy Questionnaire.

    Time frame: Baseline (T0 = day 0)

  3. Trait absorption (Tellegen Absorption Scale), both partners

    34-item true-false trait measure.

    Time frame: Baseline (T0 = day 0)

  4. Acute subjective drug effects (DEQ), both partners

    Drug Effects Questionnaire visual-analogue ratings (feel, like, high, want more).

    Time frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84

  5. Session phenomenology (PIQ, EBI, 5D-ASC, MEQ-30), both partners

    Psychological Insight Questionnaire; Emotional Breakthrough Inventory (6 items); 5-Dimensional Altered States of Consciousness Rating Scale; Mystical Experience Questionnaire-30 (exploratory for MDMA).

    Time frame: At each of the three MDMA sessions, respectively on days 28, 56 and 84

  6. General psychotherapeutic change mechanisms (GCMQ), both partners

    General Change Mechanisms Questionnaire, 25 items, five mechanisms.

    Time frame: After each treatment cycle (T1, T2, T3), respectively on days 42, 70 and 122

  7. Persisting effects (PEQ-SF), both partners

    Persistent Effects Questionnaire Short Form, 14 items plus 3 on spirituality, well-being and meaning.

    Time frame: After each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304); not at baseline

  8. Participant experience (semi-structured qualitative interview), each partner separately

    Thematic analysis of interviews following the PACT-MDMA Participant Experience Interview Guide: experience of self, of the relationship, of the MDMA sessions, of the periods between sessions; barriers and facilitators.

    Time frame: Baseline (T0 = day 0), after each treatment cycle (T1 = day 42; T2 = day 70; T3 = day 122) and 1, 3 and 6 months after the closing session (T4 = day 152; T5 = day 213; T6 = day 304)

07

Study locations

1 site
  • University of Ottawa, School of Psychology, Laboratory for Psychedelic Clinical Research
    Ottawa, Ontario K1N 6N5, Canada
    • Simon Hatcher, MD · Principal investigator
    • Jérémie Richard, PhD · Sub investigator
    • Jean-François Jodouin, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared. The study enrols 12 to 20 participants in couples, so that individual-level data carry a risk of re-identification even after de-identification; results will be reported in aggregate with small-sample disclosure safeguards, as set out in the study's data protocol.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Oct 2028, 18 months later.

Of 47 non-industry phase 1 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's planned 18 months is below that.

Counting every sponsor, half of 52 studies reached it within 33 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2026
First posted
Nov 18, 2026
StartEst.
Apr 2027
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944781
Lead sponsor
Jeremie Richard
Responsible party
Jeremie Richard (Assistant Professor, School of Psychology, University of Ottawa) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Apr 2027 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Jean-François Jodouin, PhD
Contact
jjodouin2@uottawa.ca
514-621-7704
Jérémie Richard, PhD
principal investigator · University of Ottawa
Jean-François Jodouin, PhD
study director · University of Ottawa
Simon Hatcher, MD
study director · University of Ottawa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion